title: Repeated ovarian stimulation with corifollitropin alfa in patients in a GnRH antagonist protocol: no concern for immunogenicity.
abstract: BACKGROUND
  One injection of corifollitropin alfa replaces the first seven daily FSH injections in controlled ovarian stimulation (COS) cycles. Repeated treatment with therapeutic proteins may cause immune responses or hypersensitivity reactions. We assessed the immunogenicity and safety of corifollitropin alfa treatment in up to three COS cycles.
  
  
  METHODS
  In this multicentre, phase III uncontrolled trial, patients (>60 kg) started treatment with one injection of 150 µg corifollitropin alfa on cycle Day 2 or 3 of menses and 0.25 mg ganielix on stimulation Day 5 or 6. Primary outcome measures were antibody formation against corifollitropin alfa (using highly sensitive radioimmunoprecipitation assay), hypersensitivity reactions, local tolerance and adverse events (AEs).
  
  
  RESULTS
  First, second and third COS cycles were started by 682, 375 and 198 patients, respectively. No clinically relevant immunogenicity or drug-related hypersensitivity was observed. For 192 patients undergoing their third cycle a post-treatment blood sample was negative in the anti-corifollitropin antibody assay, resulting in an upper limit of the one-sided 95% confidence interval (CI) of 1.5%. Most frequent AEs were procedural pain (17.7%, 95% CI: 14.9-20.8%), headache (9.1%, 95% CI: 7.0-11.5%) and pelvic pain (7.6%, 95% CI: 5.7-9.9%). Cumulative ongoing pregnancy rate after three cycles, including frozen-thawed embryo transfer cycles and spontaneous pregnancies, was 61% (95% CI: 56-65%) after censoring for patients who discontinued.
  
  
  CONCLUSIONS
  Treatment with corifollitropin alfa can safely and effectively initiate and sustain ovarian stimulation during the first 7 days of COS in normal responder patients undergoing up to three treatment cycles, without concerns of immunogenicity. The trial was registered under ClinicalTrials.gov identifier NCT00696878.
authors.affiliation: Robinson Institute, University of Adelaide, Australia.
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Norman
authors.forename: Fernando
authors.initials: F
authors.lastname: Zegers-Hochschild
authors.forename: Bruno S
authors.initials: BS
authors.lastname: Salle
authors.forename: Jolanda
authors.initials: J
authors.lastname: Elbers
authors.forename: Esther
authors.initials: E
authors.lastname: Heijnen
authors.forename: Maya
authors.initials: M
authors.lastname: Marintcheva-Petrova
authors.forename: Bernadette
authors.initials: B
authors.lastname: Mannaerts
mesh_terms: D000293:Adolescent; D000328:Adult; D005260:Female; D043373:Follicle Stimulating Hormone, Human / Q000009:adverse effects / Q000276:immunology* / Q000627:therapeutic use*; D006801:Humans; D010062:Ovulation Induction / Q000379:methods*; D011247:Pregnancy; D018873:Pregnancy Rate
chemical_list: D043373:Follicle Stimulating Hormone, Human; C437186:follicle stimulating hormone, human, with HCG C-terminal peptide